If you find this podcast useful please give it a rating and review on iTunes by clicking here
Vadim Alexandre, Head of Healthcare at SP Angel discusses Cambridge Cognition's #COG contract for an additional schizophrenia clinical trial worth £1.0m.
Highlights
Cambridge Cognition Holdings Plc (AIM: COG), which develops and markets digital solutions to assess brain health, is pleased to announce that it has secured a contract for an additional schizophrenia clinical trial worth £1.0m. The revenue from this contract is expected over the next three years. Cambridge Cognition will provide proprietary cognitive assessments (CANTABTM) and specialist, study management services. This contract is a repeat purchase from an existing client that has contracted for several other clinical trials for schizophrenia.
Cognitive impairment is a core feature of schizophrenia, with deficits frequently observed in memory, attention and executive functions. Cambridge Cognition has secured these contracts on the strength of the Company's reputation for quality service and its cognitive assessments (CANTABTM) capable of measuring the distinct cognitive processes compromised in schizophrenia.